Macrogenics (MGNX) Operating Expenses (2012 - 2026)

Macrogenics (MGNX) has 15 years of Operating Expenses data on file, last reported at $54.2 million in Q1 2026.

• On a quarterly basis, Operating Expenses fell 2.87% year-over-year to $54.2 million in Q1 2026; TTM through Mar 2026 was $220.7 million, a 12.92% decrease from a year earlier, with the FY2025 full-year figure at $222.3 million, down 14.66% from the prior year.
• Operating Expenses for Q1 2026 stood at $54.2 million, up from $53.3 million in the prior quarter.
• Over the last five years, Operating Expenses for MGNX reached as high as $77.7 million in Q1 2022 and fell as low as $45.9 million in Q3 2023.
• Historically, Operating Expenses has averaged $61.0 million across 5 years, with a median of $60.1 million in 2023.
• Across the five-year window, Operating Expenses slumped 31.17% in 2023 and climbed 23.13% in 2024, its largest moves.
• Year by year, Operating Expenses stood at $61.1 million in 2022, then slipped by 1.71% to $60.1 million in 2023, then climbed by 20.17% to $72.2 million in 2024, then retreated by 26.13% to $53.3 million in 2025, then grew by 1.67% to $54.2 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $54.2 million in Q1 2026, $53.3 million in Q4 2025, and $54.2 million in Q3 2025.